Regulating blood sugar: In addition to stimulating insulin, GLP-1 suppresses the secretion of glucagon, a hormone that increases blood sugar levels
And because each swap replaced something you were already eating, it sticks
Semaglutide is the active pharmaceutical ingredient in Wegovy (FDA-approved for chronic weight management) and Ozempic (FDA-approved for type 2 diabetes)
More research is needed to confirm lavender essential oil's effects when used in aromatherapy
Semaglutide: Structural Properties and Analytical Implications Injectable semaglutide structure Semaglutide is a 31-amino acid GLP-1 receptor agonist (molecular weight approximately 4,113.58 Da) derived from native human GLP-1(7-36) amide by three targeted structural modifications designed to extend half-life and resist enzymatic degradation: Aib8 (alpha-aminoisobutyric acid at position 8): Replaces the alanine residue at position 8, conferring resistance to DPP-4 (dipeptidyl peptidase-4) cleavage the primary degradation pathway for native GLP-1
safety and tolerability Key Results Weight Reduction Mean percentage change in weight at week 48: 1 mg: 8.7% 4 mg: 17.1% 8 mg: 22.8% 12 mg: 24.2% Placebo: 2.1% 100% of participants on 8 mg and 12 mg achieved 5% reduction
